Literature DB >> 11524025

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

H D Desai1, J Seabolt, M W Jann.   

Abstract

Many psychiatric patients smoke, and are believed to be heavier smokers than those without psychiatric disorders. Cigarette smoking is one of the environmental factors that contributes to interindividual variations in response to an administered drug. Polycyclic aromatic hydrocarbons (PAHs) present in cigarette smoke induce hepatic aryl hydrocarbon hydroxylases, thereby increasing metabolic clearance of drugs that are substrates for these enzymes. PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes, primarily CYP1A1, 1A2 and 2E1. Drug therapy can also be affected pharmacodynamically by nicotine. The most common effect of smoking on drug disposition in humans is an increase in biotransformation rate, consistent with induction of drug-metabolising enzymes. Induction of hepatic enzymes has been shown to increase the metabolism and to decrease the plasma concentrations of imipramine, clomipramine, fluvoxamine and trazodone. The effect of smoking on the plasma concentrations of amitriptyline and nortriptyline is variable. Amfebutamone (bupropion) does not appear to be affected by cigarette smoking. Smoking is associated with increased clearance of tiotixene, fluphenazine, haloperidol and olanzapine. Plasma concentrations of chlorpromazine and clozapine are reduced by cigarette smoking. Clinically, reduced drowsiness in smokers receiving chlorpromazine, and benzodiazepines, compared with nonsmokers has been reported. Increased clearance of the benzodiazepines alprazolam, lorazepam, oxazepam, diazepam and demethyl-diazepam is found in cigarette smokers, whereas chlordiazepoxide does not appear to be affected by smoking. Carbamazepine appears to be minimally affected by cigarette smoke, perhaps because hepatic enzymes are already stimulated by its own autoinductive properties. Cigarette smoking can affect the pharmacokinetic and pharmacodynamic properties of many psychotropic drugs. Clinicians should consider smoking as an important factor in the disposition of these drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524025     DOI: 10.2165/00023210-200115060-00005

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  84 in total

Review 1.  The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis.

Authors:  K J Aitchison; B D Jordan; T Sharma
Journal:  Drug Metabol Drug Interact       Date:  2000

2.  Influence of patient-related variables on clozapine plasma levels.

Authors:  C Haring; W W Fleischhacker; P Schett; C Humpel; C Barnas; A Saria
Journal:  Am J Psychiatry       Date:  1990-11       Impact factor: 18.112

3.  Plasma levels of imipramine in depression. Environmental and genetic factors.

Authors:  J M Perel; J Mendlewicz; M Shostak; S J Kantor; A H Glassman
Journal:  Neuropsychobiology       Date:  1976       Impact factor: 2.328

4.  Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.

Authors:  M W Jann; G S Fidone; J M Hernandez; S Amrung; C M Davis
Journal:  Psychiatry Res       Date:  1989-05       Impact factor: 3.222

5.  Drowsiness due to chlorpromazine in relation to cigarette smoking. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  C Swett
Journal:  Arch Gen Psychiatry       Date:  1974-08

6.  Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics of clomipramine and its desmethyl metabolite during chronic dosing.

Authors:  V A John; D K Luscombe; H Kemp
Journal:  J Int Med Res       Date:  1980       Impact factor: 1.671

7.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

8.  Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report.

Authors:  G L Stimmel; I R Falloon
Journal:  J Clin Psychiatry       Date:  1983-11       Impact factor: 4.384

9.  Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables.

Authors:  L Ereshefsky; S R Saklad; M D Watanabe; C M Davis; M W Jann
Journal:  J Clin Psychopharmacol       Date:  1991-10       Impact factor: 3.153

10.  A pharmacokinetic study of trifluoperazine in two ethnic populations.

Authors:  K K Midha; E M Hawes; J W Hubbard; E D Korchinski; G McKay
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  52 in total

1.  A comprehensive model for mental health tobacco recovery in new jersey.

Authors:  Jill M Williams; Mia Hanos Zimmermann; Marc L Steinberg; Kunal K Gandhi; Cris Delnevo; Michael B Steinberg; Jonathan Foulds
Journal:  Adm Policy Ment Health       Date:  2011-09

2.  Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study.

Authors:  Delbert G Robinson; Nina R Schooler; Majnu John; Christoph U Correll; Patricia Marcy; Jean Addington; Mary F Brunette; Sue E Estroff; Kim T Mueser; David Penn; James Robinson; Robert A Rosenheck; Joanne Severe; Amy Goldstein; Susan Azrin; Robert Heinssen; John M Kane
Journal:  Am J Psychiatry       Date:  2014-12-04       Impact factor: 18.112

3.  Smoking cessation in patients with psychiatric disorders.

Authors:  Alan J Gelenberg; Jose de Leon; A Eden Evins; Joseph J Parks; Nancy A Rigotti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 4.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 5.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 6.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

7.  Smoking, psychiatric illness and the brain.

Authors:  Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2017-05       Impact factor: 6.186

8.  A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis.

Authors:  John R Tomko; Nadeem Ahmed; Cynthia Kuntz; Justine Zick
Journal:  Hosp Pharm       Date:  2016-11

Review 9.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 10.  [Why do schizophrenic patients smoke?].

Authors:  K Cattapan-Ludewig; S Ludewig; E Jaquenoud Sirot; M Etzensberger; F Hasler
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.